YouTube video by OraTech

YouTube video by OraTech

YouTube video by OraTech

In a recent communication, Oramed Pharmaceuticals outlined major achievements and future plans, including the formation of a new joint venture aiming to innovate oral insulin delivery.

Oramed Pharmaceuticals has launched a new venture, OraTech Pharmaceuticals, to innovate oral insulin delivery. This strategic collaboration should enhance diabetes treatment globally.

Lifeward (Nasdaq:LFWD) reported Q1 2026 revenue of $3.9 million, down 22% year-over-year, with gross margin of 34.2%. ReWalk personal exoskeleton sales rose 11% to $1.6 million, while AlterG revenue fell 38% to $2.1 million.The company closed its Oratech strategic transaction, adding $6.5 million in cash and the Protein Oral Delivery platform, and received $10 million in financing. Operating cash burn fell 33% year-over-year, and unrestricted cash increased to $11.4 million. Lifeward will delay filing its Q1 2026 Form 10-Q to finalize accounting for the March 2026 transaction.

Oramed Pharmaceuticals (NASDAQ: ORMP) has announced key developments expected for completion in 2025, centered around its new joint venture OraTech Pharmaceuticals. The venture focuses on oral insulin development with planned U.S. Phase 3 trials.Key highlights include:Distribution of majority OraTech holdings to Oramed shareholders via dividend, coinciding with OraTech's planned Nasdaq listingPlanned cash dividend of approximately $0.25 per shareMarketing Authorization Application submitted by HTIT for oral insulin capsule in China, with OraTech expected to receive royaltiesOngoing revenue from Scilex partnership, including $400,000 in royalties due for Q4 2024The company maintains a strong financial position through its Scilex transaction, receiving $70 million from a $99.5 million loan agreement, with additional $53 million expected over two years. Oramed holds 12.25 million Scilex shares, increasing to 18.75 million shares, plus royalty streams from multiple products including ZTlido, ELYXYB, and GLOPERBA.

Oramed launches OraTech Pharmaceuticals with $75M backing, securing manufacturing partnership and advancing oral insulin development with revised Phase 3 trial.

New Standalone Company, OraTech Pharmaceuticals Inc., to Focus on Oral Drug Delivery with Strategic Investment and Advanced Manufacturing Capabilities Oramed shareholders to receive the right to a direct stake in OraTech, expected to go public on Nasdaq.…